Press release


19/10/2012
ORYZON and CANCER RESEARCH UK’S Paterson Institute for Cancer Research have started a collaborative research project on therapeutic uses of LSD1 inhibitors for Acute Leukaemia
Logo Oryzon
The Cancer Research UK-funded research is led by Dr Tim Somervaille, Group Leader of the Cancer Research UK Leukaemia Biology group at the Paterson Institute for Cancer Research and Honorary Consultant in Haematology at The Christie NHS Foundation Trust in Manchester (UK).
The collaboration is focused to achieve a deeper understanding of the inhibition of histone lysine demethylation as a stopper mechanism for onset and progression of acute leukaemia.
 
Oryzon announces that ORYZON and Cancer Research UK’s Paterson Institute for Cancer Research have entered into a collaboration to further study the potential of highly potent and highly-selective Oryzon LSD1 inhibitors in the treatment of acute leukemia. This collaborative research is performed by Dr Tim Somervaille’s group.
Cancer Research UK scientist Dr Tim Somervaille is a specialist in leukaemia and in LSD1. He was trained in Medicine at St Mary’s Hospital Medical School (Imperial College London) and University College London. He specialised in Clinical Haematology at University College London, where he also obtained a PhD as a Medical Research Council Clinical Training Fellow. Later, as a Leukaemia Research Fund Senior Clinical Fellow, he spent four years in Professor Michael Cleary’s laboratory undertaking postdoctoral studies in leukaemia. Currently he is leader of the Cancer Research UK Leukaemia Biology group at Cancer Research UK’s Paterson Institute for Cancer Research and also Honorary Consultant in Haematology at The Christie NHS Foundation Trust.
Recently, in independent research that was published in Cancer Cell, Dr. Somervaille demonstrated that molecules discovered and patented by Oryzon were efficient in the treatment of acute myeloid leukaemia (AML), which represents 40% of all leukaemias in humans, and especially an aggressive form of acute myeloid leukaemia called mixed lineage leukaemia (MLL), pointing to a significant potential therapeutic window for the use of LSD1 inhibitors in the MLL molecular subtype of AMLs.
The collaborative program aims to better understand the mechanism by which LSD1 inhibitors are affecting the diverse molecular types of acute leukaemia and other haematological malignancies and to determine in which disease subtypes these drugs could be more effective. Different in vitro and in vivo models will be used to assess the efficacy of various Oryzon advanced LSD1 inhibitors.
Last May, Oryzon announced the nomination of a preclinical candidate for development that is currently in regulatory safety studies and it is expected to be ready for the first tests in humans in early 2013.
The current collaboration agreement contemplates the possibility that The Christie NHS Foundation Trust - a specialist cancer hospital serving the North West of England - be chosen to perform the Phase I/IIA studies planned for next year.
An overview of Oryzon’s LSD1 program will be presented at the 2nd Cancer Epigenetics conference in Nov 08-09, Boston, MA, USA and at the 4th World Epigenetics Summit in Dec, 3rd in London UK.
 
 
 
 
Permalink  
 
Developed by Web4Bio